2021 ASCO Virtual Annual Meeting*

Download All
June 4-8, 2021; Online at https://conferences.asco.org/am
Review slidesets and expert analyses of key data from the 2021 Clinical Oncology Virtual Scientific Meeting!

Lung Cancer

Capsule Summary Slidesets

BOS127238, a novel, highly selective RET inhibitor, was associated with a manageable safety profile and preliminary efficacy in a phase I study in RET-altered solid tumors.

Released: June 8, 2021

Results of this preplanned interim analysis demonstrated significantly improved DFS with adjuvant atezolizumab in patients with stage II-IIIA NSCLC, particularly for individuals with PD-L1–positive tumors.

Released: June 9, 2021

Longer-term results from PACIFIC show sustained OS and PFS benefit—with 5-year OS and PFS rates of 42.9% and 33.1%, respectively—with concurrent CRT followed by 1 year of durvalumab.

Released: June 6, 2021

Pembrolizumab + concurrent CRT followed by pembrolizumab consolidation conferred encouraging antitumor activity regardless of nonsquamous or squamous histology and PD-L1 expression levels.

Released: June 5, 2021

First-line nivolumab plus ipilimumab with chemotherapy continued to provide durable clinical benefit in patients with advanced NSCLC regardless of PD-L1 expression with extended follow-up.

Released: June 10, 2021

Results of this retrospective exploratory analysis suggest that chemo-IO regimens may improve OS and PFS compared with IO alone in most patients with previously untreated advanced NSCLC and tumor PD-L1 expression 1% to 49%.

Released: June 5, 2021

Clinical benefit of sotorasib in patients with previously treated KRAS p.G12C–mutated NSCLC observed across subgroups prespecified by baseline characteristics and in exploratory analyses of molecularly defined subgroups.

Released: June 7, 2021

Multivariable regression analyses of deidentified health record data showed that Black patients with NSCLC were less likely to receive NGS-based genetic testing or enroll on clinical trials than White patients.

Released: June 15, 2021

Amivantamab plus lazertinib achieved an ORR of 36% in chemotherapy-naive patients with disease progression on first-line osimertinib.

Released: June 9, 2021

Updated phase I results with extended follow-up show antitumor activity of patritumab deruxtecan in patients with previously treated locally advanced or metastatic EGFR-mutated NSCLC across various EGFR TKI resistance mechanisms and regardless of prior therapy or presence of CNS metastases.

Released: June 8, 2021

First-line nivolumab plus ipilimumab continued to provide durable clinical benefit in patients with advanced NSCLC regardless of PD-L1 expression level with extended follow-up.

Released: June 10, 2021

Phase I results from TROPION-PanTumor01 suggest durable antitumor activity and a manageable safety profile with datopotamab deruxtecan in patients with previously treated advanced NSCLC.

Released: June 8, 2021
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Amgen
AstraZeneca
Bristol-Myers Squibb
Daiichi Sankyo, Inc.
Ipsen Biopharmaceuticals, Inc.
Merck Sharp & Dohme Corp.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue